(Cost) Effectiveness Assessment in Health
- Adler, M. D. (2011). Well-Being and Fair Distribution: Beyond Cost-Benefit Analysis. New York, NY: Oxford University Press.
- Brock, D. W. (2004). Ethical Issues in the Use of Cost Effectiveness Analysis for the Prioritization of Health Care Resources. Public Health, Ethics, and Equity. S. Anand, F. Peter and A. K. Sen. Oxford: Oxford University Press.
- Broome, J. (1993). QALYs. Journal of Public Economics 50, 149-167.
- Drummond, M. F., Sculpher, M., O’Brien, B., Stoddart, G. L. and Torrance, G. W. (eds.) (2005). Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press.
- Eyal, N. (2012). Global health impact labels. In E. J. Emanuel & J. Millum (Eds.), Global Justice in Bioethics. New York, NY: Oxford University Press: 241–78.
- Gold, M. R., Siegel, J. E., Russell, L. B. and Weinstein, M. C. (eds.) (1996). Cost-effectiveness in health and medicine. Oxford: Oxford University Press.
- Goldhaber-Fiebert, J. D., N. K. Stout, et al. (2010). "Empirically evaluating decision-analytic models." Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research 13(5): 667-674.
- Hassoun, N. (2014). Globalization and Global Justice: Shrinking Distance, Expanding Obligations. Cambridge: Cambridge University Press.
- Hauber, A. B. (2009). Healthy-years equivalent: Wounded but not yet dead. Expert Review of Pharmacoeconomics Outcomes Research 9, 265–269.
- Hollis, A., & Pogge, T. (2008). The Health Impact Fund: Making new medicines accessible for all. New Haven, CT: Incentives for Global Health (IGH).
- Jamison, D. T., Ed. (2006). Disease Control Priorities in Developing Countries (DCP2). Washington DC, World Bank and Oxford University Press.
- Jamison D. T. (Ed.) (Forthcoming). Disease Control Priorities in Developing Countries (DCP3) (3rd edition).
- Jamison, D. T., Breman, J. G., Measham, A. R., Alleyne, G., et al (Eds.). (2006). Disease control priorities in developing countries (2nd edition). New York: Oxford University Press.
- Kim, J. Y., P. Farmer, et al. (2013). Redefining global health-care delivery. Lancet 382(9897): 1060-9.
- Kim, S. Y. & Goldie, S. J. (2008). "Cost-effectiveness analyses of vaccination programmes: a focused review of modelling approaches." PharmacoEconomics 26(3): 191-215.
- Lozano, R., Naghavi, M., et al (2012). Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 380(9859), 2095–2128.
- Mckie, J., Richardson, J., Singer, P., & Kuhse, H. (1998). The Allocation of Health Care Resources. An Ethical Evaluation of the "QALY" Approach. Aldershot: Ashgate Publishing Company.
- Murray, C. J., Ezzati, M., et al (2012). GBD 2010: design, definitions, and metrics. Lancet, 380(9859), 2063–2066.
- Murray CJ, Ezzati M, et al. (2012). GBD 2010: a multi-investigator collaboration for global comparative descriptive epidemiology.
- Neumann, P. J., Greenberg, D., Olchanski, N. V., Stone, P. W. and Rosen, A. B. (2005). Growth and quality of the cost-utility literature, 1976-2001. Value in Health 8, 3–9.
- Nord, E. (1999). Cost-value analysis in health care: Making sense out of QALYs. Cambridge: Cambridge University Press.
- Nord, E., Daniels, N. and Kamlet, M. (2009). QALYs: Some challenges. Value in Health 12(Supplement), S10–S15.
- Nord, E., and R. Johansen. (2014). Concerns for severity in priority setting in health care: A review of trade-off data in preference studies and implications for societal willingness to pay for a QALY. Health policy 116 (2–3):281–288.
- Nord, E. and R. Johansen (2014). "Transforming EQ-5D utilities for use in cost–value analysis of health programs." The European journal of health economics: HEPAC: health economics in prevention and care.
- Nord, E., Pinto, J. L., Richardson, J., Menzel, P. and Ubel, P. (1999). Incorporating societal concerns for fairness in numerical valuations of health programs. Health Economics 8, 25–39.
- Nord, E., J. Richardson, et al. (1995). "Who cares about cost? Does economic analysis impose or reflect social values?" Health Policy 34: 79–94.
- Ord, T. (Unpublished). "The moral imperative towards cost-effectiveness”.
- Salomon JA, Wang H, et al. (2012). Healthy life expectancy for 187 countries, 1990-2010: a systematic analysis for the Global Burden Disease Study 2010. Lancet; 380(9859):2144-62.
- Singer, P. (2010). The life you can save: how to do your part to end world poverty. New York: Random House.
- Ubel, P. A., M. L. DeKay, et al. (1996). Cost-effectiveness analysis in a setting of budget constraints--is it equitable? New England Journal of Medicine, 334(18): 1174-1177.
- Vos T, Flaxman AD, et al (2012). Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet; 380(9859): 2163-96.